Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124

Moderna Inc. headquarters In Cambridge, Massachusetts, on March 26, 2024.
Adam Glonzman Bloomberg | Ghetto images
Modern On Thursday said he plans to reduce approximately 10% of his worldwide workforce by the end of the year as Covid launched sales Continue to reduce And the company is struggling with insecurity in the vaccine market.
In note For employees, Moderna’s CEO Stephane Bancel said the company expects to have less than 5,000 workers by the end of the year. Moderna had approximately 5,800 full -time employees in 18 countries as of December 31, 2024, according to his 2024 Annual ReportS
Moderna’s shares dropped over 20% this year. In May, the company reported sales of the vaccine in the first quarter, which missed Wall Street assessments. Moderna also moves Obstacles to a policy According to the Secretary of Health and Human Services, Robert F. Kennedy, Jr., who has taken steps to change vaccine guidelines and potentially threatens access to photos in the United States
Also in May, Moderna said it would reduce annual operating costs by about $ 1.5 billion by 2027. This goal adds to the abbreviations that the company earlierS
Moderna will provide another update to its business when posting quarterly results on Friday morning.
In the note., Bancel said Moderna has made significant progress to cuts by reducing research and development, especially after completing respiratory attempts, renegotiated suppliers agreements and reducing production costs.
“All efforts were made to avoid affecting jobs,” he said. “But today, the transformation of our operational structure and alignment of our cost to the realities of our business are essential to remain focused and financially disciplined, while continuing to invest in our science on the path by 2027”
He said “the future of modernity is bright”, noting that there are now three approved products and potential for up to eight in the next three years. In May, the Food and Drug Administration approved Moderna’s third product, a next -generation cow shot.
But Bankl said “this decision was not made lightly.”
“This affects teammates and friends who have devoted themselves to our mission and who have helped build a modern one,” he said. “I want to express on behalf of the whole Executive Committee and on behalf of the patients you have served, our deepest thanks for everything you have contributed.”